TET2 and breast carcinoma: Restoring 5hmC levels by overexpressing TET2 in melanoma cells, TET1 in breast cancer cells, and IDH1 in renal cancer cells demonstrated inhibitory effects in vitro and in vivo [11, 12, 24].